These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17583228)

  • 1. Less weight or more hype with rimonabant?
    Drug Ther Bull; 2007 Jun; 45(6):41-3. PubMed ID: 17583228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rimonabant for overweight or obesity.
    Curioni C; André C
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006162. PubMed ID: 17054276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimonabant for the treatment of overweight and obese people.
    Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
    Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 10. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic risk factors, drugs, and obesity.
    Padwal R; Majumdar S
    N Engl J Med; 2006 Mar; 354(9):974-5; author reply. PubMed ID: 16510755
    [No Abstract]   [Full Text] [Related]  

  • 12. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 13. Pleiotropic effects of rimonabant: clinical implications.
    Després JP
    Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
    Rubio MA; Gargallo M; Isabel Millán A; Moreno B
    Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
    Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
    Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nutrition-obesity. Rimonabant and cardiovascular risk factors].
    Vincent M; Golay A
    Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
    Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
    Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.